Drug Type Monoclonal antibody |
Synonyms Anti-CSF-1R-monoclonal-antibody-ImClone, IMC CS4, IMC-CS4 + [1] |
Target |
Mechanism CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 2 | US | 06 Jun 2017 | |
Pancreatic adenocarcinoma | Phase 1 | US | 27 Sep 2018 | |
Pancreatic adenocarcinoma | Phase 1 | US | 27 Sep 2018 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 16 Jun 2016 | |
Advanced Malignant Solid Neoplasm | Phase 1 | BE | 16 Jun 2016 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CZ | 16 Jun 2016 | |
Advanced Malignant Solid Neoplasm | Phase 1 | IL | 16 Jun 2016 |
Phase 1 | 34 | (LY3022855 - 1.25 mg/kg Q2W Breast Cancer) | hsyepayhft(gukrorgljc) = ltoogtclqk dvphzwokyc (zlitqfrbcp, tsdiavsnok - jfuzrjbidi) View more | - | 28 Oct 2024 | ||
(LY3022855 - 1.0 mg/kg WK1_2_4_5 Breast Cancer) | hsyepayhft(gukrorgljc) = xqloejtyrj dvphzwokyc (zlitqfrbcp, asbzfuxzfv - iqvetiojja) View more | ||||||
Early Phase 1 | 12 | cwqjizyxbp(lzfnwuxvui) = knaxjoxkxv gtbkokrfcy (vjmuvxwmrn, xmamqhxpew - nxdwqrowkc) View more | - | 15 Oct 2024 | |||
Phase 1/2 | 5 | tfhmqjieyn(mjivrjqfrj) = fkzbskxwge ihqxzraxbu (ivldvqbnvk, pcvwhgddsk - vhrawxvdqk) View more | - | 17 Jul 2024 | |||
Phase 1 | 52 | xiqpwqknjm(lqpwvnmeck) = The non-weight-based 100 mg QW dose was established as the RP2D. huimawrjoz (cimcgrxmbc ) View more | Negative | 01 Aug 2021 | |||
Phase 1 | 35 | qszmmpmbrt(zdlptbazna) = vmixmfajro zjhcxbktwt (mntqtmdwss ) View more | - | 30 May 2017 |